Monte Rosa Therapeutics (GLUE) Total Liabilities (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Total Liabilities of $214.5 million for Q1 2026, up 81.73% year-over-year from $118.0 million in Q1 2025, and down 0.51% quarter-over-quarter from $215.6 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Total Liabilities (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $214.5 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 81.73% year-over-year to $214.5 million; the TTM figure through Mar 2026 stood at $214.5 million (up 81.73% YoY), while the FY2025 annual figure was $215.6 million, changed 0.09% from the prior year.
- Total Liabilities for Q1 2026 stood at $214.5 million, down from $215.6 million in the prior quarter.
- The five-year high for Total Liabilities was $215.8 million in Q4 2024, with the low at $20.1 million in Q1 2022.
- The 5-year median for Total Liabilities is $109.6 million (2024), against an average of $115.0 million.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities surged 413.79% in 2022, then dropped 23.39% in 2025.
- Monte Rosa Therapeutics' Total Liabilities stood at $71.0 million in 2022, then jumped by 75.42% to $124.5 million in 2023, then jumped by 73.32% to $215.8 million in 2024, then retreated by 0.09% to $215.6 million in 2025, then decreased by 0.51% to $214.5 million in 2026.
- Business Quant data shows GLUE's Total Liabilities at $214.5 million in Q1 2026, $215.6 million in Q4 2025, and $214.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | 203.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 203.88 Mn |
| Mar 31, 2026 | 214.51 Mn |
| Dec 31, 2025 | 215.60 Mn |
| Sep 30, 2025 | 214.00 Mn |
| Jun 30, 2025 | 91.51 Mn |
| Mar 31, 2025 | 118.04 Mn |
| Dec 31, 2024 | 215.80 Mn |
| Sep 30, 2024 | 109.62 Mn |
| Jun 30, 2024 | 119.44 Mn |
| Mar 31, 2024 | 114.23 Mn |
| Dec 31, 2023 | 124.51 Mn |
| Sep 30, 2023 | 67.58 Mn |
| Jun 30, 2023 | 64.96 Mn |
| Mar 31, 2023 | 65.30 Mn |
| Dec 31, 2022 | 70.98 Mn |
| Sep 30, 2022 | 66.51 Mn |
| Jun 30, 2022 | 63.01 Mn |
| Mar 31, 2022 | 20.13 Mn |
| Dec 31, 2021 | 18.81 Mn |
| Sep 30, 2021 | 14.74 Mn |